GeneDx Holdings/$WGS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About GeneDx Holdings
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Ticker
$WGS
Sector
Primary listing
Industry
Health Care Providers & Services
Headquarters
Employees
1,000
ISIN
US81663L2007
Website
GeneDx Holdings Metrics
BasicAdvanced
$2.6B
-
-$1.41
2.04
-
Price and volume
Market cap
$2.6B
Beta
2.04
52-week high
$117.75
52-week low
$25.21
Average daily volume
947K
Financial strength
Current ratio
3.247
Quick ratio
2.95
Long term debt to equity
43.399
Total debt to equity
44.613
Interest coverage (TTM)
-4.29%
Profitability
EBITDA (TTM)
8.288
Gross margin (TTM)
65.27%
Net profit margin (TTM)
-11.68%
Operating margin (TTM)
-4.00%
Effective tax rate (TTM)
-0.48%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
-1.96%
Return on equity (TTM)
-16.61%
Valuation
Price to revenue (TTM)
7.564
Price to book
10.1
Price to tangible book (TTM)
25.4
Price to free cash flow (TTM)
-190.954
Free cash flow yield (TTM)
-0.52%
Free cash flow per share (TTM)
-47.71%
Growth
Revenue change (TTM)
48.81%
Earnings per share change (TTM)
-73.10%
3-year revenue growth (CAGR)
17.80%
3-year earnings per share growth (CAGR)
-61.92%
Bulls say / Bears say
GeneDx achieved its profitability milestone with adjusted net income in 2024, indicating strong financial health and operational efficiency. (gurufocus.com)
The company reported revenues of at least $299 million for 2024, marking a 54% increase year-over-year, showcasing significant growth momentum. (gurufocus.com)
Exome and genome test revenues increased by 93% year-over-year in Q4 2024, reflecting strong demand for GeneDx's specialized testing services. (gurufocus.com)
Despite revenue growth, GeneDx reported a net loss of $52.29 million in FY 2024, indicating ongoing profitability challenges. (stockanalysis.com)
The company's operating margin for the trailing twelve months is -3.76%, suggesting inefficiencies in managing operational costs. (forbes.com)
GeneDx's total debt stands at $114.84 million, with a debt-to-equity ratio of 44.61%, which may pose financial risks if not managed effectively. (forbes.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.
GeneDx Holdings News
AllArticlesVideos
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
GlobeNewsWire·16 hours ago
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
GlobeNewsWire·5 days ago
Insiders Invested Millions in these Five Rebounding Stocks
24/7 Wall Street·5 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for GeneDx Holdings stock?
GeneDx Holdings (WGS) has a market cap of $2.6B as of June 30, 2025.
What is the P/E ratio for GeneDx Holdings stock?
The price to earnings (P/E) ratio for GeneDx Holdings (WGS) stock is 0 as of June 30, 2025.
Does GeneDx Holdings stock pay dividends?
No, GeneDx Holdings (WGS) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next GeneDx Holdings dividend payment date?
GeneDx Holdings (WGS) stock does not pay dividends to its shareholders.
What is the beta indicator for GeneDx Holdings?
GeneDx Holdings (WGS) has a beta rating of 2.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.